logo
Plus   Neg
Share
Email

CytomX Therapeutics Inc. (CTMX) Is Climbing On Amgen Collaboration News

CytomX Therapeutics Inc. (CTMX) announced after the bell Tuesday that it has entered into a strategic collaboration with Amgen (AMGN) in immuno-oncology. The stock is now up 6.02 on 72K shares.

CytomX Therapeutics dipped in early trade Tuesday, but settled into a range for the majority of the session. Shares finished with a loss of 0.25 at $19.00. The stock pulled back slightly from resistance at the highs of the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT